loading page

Induction of Remission after Donor Lymphocyte Infusion Following Allogeneic Transplant in a case of Pediatric Primary Myelofibrosis.
  • +3
  • Amy Li,
  • Sei-Gyung K. Sze,
  • Malika Kapadia,
  • Leslie Lehmann,
  • Jacob Bledsoe,
  • Alyssa L. Kennedy
Amy Li
Dana-Farber/Boston Children's Cancer and Blood Disorders Center
Author Profile
Sei-Gyung K. Sze
Maine Medical Center
Author Profile
Malika Kapadia
Dana-Farber/Boston Children's Cancer and Blood Disorders Center
Author Profile
Leslie Lehmann
Dana-Farber/Boston Children's Cancer and Blood Disorders Center
Author Profile
Jacob Bledsoe
Boston Children's Hospital Department of Pathology
Author Profile
Alyssa L. Kennedy
St Jude Children's Research Hospital

Corresponding Author:alyssa.kennedy@stjude.org

Author Profile

Abstract

Pediatric primary myelofibrosis (PMF) is an extremely rare entity which differs from adult disease in both etiology and outcome.[[1, 2]](https://paperpile.com/c/kO3nmc/v7ZT+LtZX) We report a case of aggressive primary pediatric myelofibrosis driven by somatic trisomy 8, JAK2 and SETBP1 mutations. Disease relapsed +45 days post hematopoietic stem cell transplant. Fortunately, our patient responded to weaning immunosuppression and donor lymphocyte infusion (DLI) and remains in remission with only mild liver and skin graft-versus-host-disease (GVHD). This case is unique not only in its similarity to adult disease but in the response to DLI as salvage therapy.
Submitted to Pediatric Blood & Cancer
Submission Checks Completed
Assigned to Editor
Reviewer(s) Assigned
04 Jul 2024Review(s) Completed, Editorial Evaluation Pending
07 Jul 2024Editorial Decision: Revise Minor
15 Jul 20241st Revision Received
15 Jul 2024Submission Checks Completed
15 Jul 2024Assigned to Editor
22 Jul 2024Review(s) Completed, Editorial Evaluation Pending
24 Jul 2024Editorial Decision: Accept